Autopsy report · NCT04694586

Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide

“Suspended 15th of Nov 2023 due to conditions affecting recruitment process.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years before it started.
• Suspended: paused, and may or may not restart.
• 40 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2

Sponsor

University Hospital, Linkoeping

Sponsor type

University, hospital or other

Conditions

Tuberculosis, Pulmonary

Interventions

rifampicin; pyrazinamide; HRZE; HR

Participants

40 (planned, not actual)

Sites

1

Countries

Sweden

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.